A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
A Phase Ib Study of Extending Relugolix Dosing Intervals Through Addition of the CYP3A4 and Pg-P Inhibitor Itraconazole or Ritonavir in Prostate Cancer Patients
Sponsor: University of Chicago
Terminated
Terminated by the PI
Other terminated trials from University of Chicago
Other Prostate Adenocarcinoma trials with similar outcome
A PHASE1 clinical study on Prostate Adenocarcinoma and Prostate Cancer, this trial is terminated or withdrawn. The trial is conducted by University of Chicago and has accumulated 6 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Oct 2024 — Present [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
Mar 2023 — Nov 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Feb 2023 — Mar 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .